At an arterial plasma concentration of 61 nmol/1 (100 ng/ml) synthetic cyclic somatostatin completely abolished basal glucagon and gastrin release as well as carbamylcholineinduced glucagon and gastrin release from the isolated perfused dog stomach. These observations are compatible with the view that endogenous somatostatin previously reported to be released during vagal stimulation might be involved to explain the lack of gastric-glucagon response in this situation. They do not, however, rule out the alternative proposal that the dog fundic A-cell may simply be a non-innervated cell.
SUMMARY At an arterial plasma concentration of 61 nmol/1 (100 ng/ml) synthetic cyclic somatostatin completely abolished basal glucagon and gastrin release as well as carbamylcholineinduced glucagon and gastrin release from the isolated perfused dog stomach. These observations are compatible with the view that endogenous somatostatin previously reported to be released during vagal stimulation might be involved to explain the lack of gastric-glucagon response in this situation. They do not, however, rule out the alternative proposal that the dog fundic A-cell may simply be a non-innervated cell.
We have previously reported that the electrical stimulation of both dorsal and ventral vagal trunks of the isolated perfused dog stomach does not elicit gastric-glucagon release, although gastrin release is markedly stimulated.' In contrast, the intra-arterial infusion of acetyl-(or carbamyl-) choline unequivocally stimulated the release of glucagon and gastrin from the isolated stomach.2' Among the possible explanations for this discrepancy, we have suggested that somatostatin, also released in our system by the electrical stimulation of the vagus nerves, might simultaneously inhibit gastric-glucagon release. ' 4 The present experiments were performed in order to see if exogenous somatostatin intra-arterial infusion would modify glucagon and gastrin release from the isolated perfused canine stomach, in response to an intra-arterial infusion of carbamylcholine, an analogue of the physiological neurotransmitter, acetylcholine. their arterial and venous supply and perfused with whole blood collected from large blood-donor dogs according to a procedure previously described in detail. The perfusing blood was supplemented with 1000 U/ml Trasylol (Bayer, Leverkusen, West Germany) and anti-insulin serum (guineapig anti-insulin serum GPAIS 567 from PH Wright, Indianapolis, In., obtained through the courtesy of W Malaisse, Brussels or guinea-pig anti-insulin serum LAA obtained from L Heding, Novo Research Institute, Copenhagen); 50 ,ul of the original sera diluted in 20 ml saline containing 1 g albumin/dl (lot PL 77 C24 from Institut Merieux, Lyon, France) were added to the blood reservoir; based on the neutralising capacities of these antisera, the quantity added represented an excess of 20 to 30 times the amount needed to neutralise the endogenous insulin present in the system.'; Immediately after the beginning of the perfusion, the glucose concentration of the perfusing blood was measured (see below) and eventually adjusted to 3.6-42 mmol/l (65-75 mg/ 100 ml) by addition to the blood reservoir of a given volume of either saline or a 10% (wt/vol) glucose solution in distilled water. The blood glucose was kept constant throughout the experiment by infusing into the blood reservoir a 66 mmol/l (12 mg/ml) glucose solution at the rate of 0.5 ml/ min; this amount was previously found adequate to compensate for glucose consumption by both the stomach and the blood cells.'; The blood flow through the isolated stomach at the beginning of the experiment was set by adjusting the perfusion 793 group.bmj.com on September 21, 2017 -Published by http://gut.bmj.com/ Downloaded from rate at a level for which the perfusion pressure was identical with the systolic blood pressure recorded before the experiment in the stomach donor dog. Thereafter, the pump rate was kept constant; further changes in blood flow or pressure thus reflected chainges in the resistance of the stomalch vessels. Blood sampling started only after a 45-60 minute equilibration period during which the blood was recirculated. After this equilibration period, basal blood samples were simultaneously collected from the artery and the vein. After collecting basal samples. catrbamylcholine was infused intra-airterially (see below) and venous samples were collected continuously at intervals of 10-30 seconds. without recirculaition of the blood. Samples were also collected at frequent intervals during the two minutes after the end of the carbamylcholine infusion.
Methods

EXPER I M ENTAL PROTOCOLS
In four experiments, carbamylcholine alone was tested. Carbamylcholine chloride (C 4382, Sigma Chemicals Co, St Louis, Mo) was dissolved in 155 mmol/l (0.9 g/100 ml) NaCI solution; this solution was infused intra-arterially at a rate of 1 ml/min for five minutes, the concentration being adjusted to reach a final concentration of 5 10-'; M in the arterial plasma. In six experiments, somaitostatin was infused in combination with carbamylcholine. Synthetic cyclic somatostatin (CM 9357, lot RKA 06, Clin Midy, Paris, France) was dissolved in 155 mmol/l (0.9 g/100 ml) NaCI supplemented with 0.25 g human purified albumin/dl (Lot PL 76 E 12, Institut Merieux, Lyon, France); this solution was infused intra-arterially at a raite of 1 ml/min, the concentration being adjusted to reach a final concentration of 61 nmol/1 (or 100 ng/ml) in the arterial plasma; the somatostatin infusion started 20 minutes before the carbamylcholine infusion, performed under the conditions mentioned above, and lasted till the end of the experiment.
ASSAYS AND CALCULATIONS As previously described,> hormone production was calculated by multiplying the venoarterial difference in plasma hormone concentration by the plasma flow (the latter being derived from the blood flow and the haematocrit). Blood glucose concentration was determined by the hexokinase method adapted to the Technicon AutoAnalyzer (Technicon Instrument Co, Tarrytown, NY). For hormone assays, 04 ml of a solution containing Trasylol, 5000 U/ml, and Na,EDTA, 35.5 mmol/l (or 12 mg/ml) were added to 3-6 ml blood. The mixture was immediaitely centrifuged at 40C, and the separated plasma was stored at -200C. Plasma glucagon was determined in duplicate assays by a classical immunoaissay procedure, using porcine 1'I1 iodoglucagon (NEN Chemicals, D-6072, Dreieichenhain, West Germany) as tracer, 30K antiserum (provided by Dr R H Unger, Dallas, Texas) and dextran-charcoal separation of free and antibody-bound hormone. Plasma gastrin was assayed in duplicate using a commercial kit (Gask, Institut National des Radioelements, Fleurus, Belgium); human gastrin 1-17 was used as standard and 12|1-labelled human gastrin as tracer; an anti-human gastrin was used as antibody and the separation of free and antibody-labelled hormone was performed using dextran-charcoal.The identity of reactivity between dog and human gastrin was assayed by verifying the parallelism of dilution curves. Plasma insulin was assayed as previously described." Statistical evaluation included variance ainalysis and Student's t test for unpaired data. All results are expressed as mean-+standard error of the mean (SEM).
Results
The haemoglobin 02 saturation of the perfusing blood was over 98% throughout all the experiments. Blood glucose averaged 3.8-+017 mmol/l or 68.6±3.1 mg/100 ml (n=10; range 58-85). Plasma glucagon in the perfusing blood, before introduction of the stomach in the circuit, averaged 82+18 pg/ml (n=10, range 5-181), plasma gastrin averaged 101-4+1-8 pg/mI (n=10; range 0-21), and plasma insulin averaged 10l142.4 uU/ml (n=10; range 24-257). As stated in the Methods section, an excess of anti-insulin serum was added to the perfusing blood in order to neutralise these small amounts of circulating plasma insulin.
BLOOD FLOW
Basal blood flow was 54+4 ml/min/100 g (n=4) before carbamylcholine infusion; it was 57+7 ml/ min/100 g (n=6) during somatostaitin infusion alone. As shown in Fig. I . carbamylcholine induced a 45% increase in blood flow; this carbamylcholine-induced rise in blood flow was not statistically affected by somatostatin.
G ASTR I C-GLUCAGO N RELEASE Basal gastric-glucagon release averaged 340+ 116 pg/100 g/min; in the somatostatin experiments it was abolished to 5+-61 pg/100 g/min (P<0-005). As illustrated in Fig. 2 , carbanmylcholine induced a progressive rise in gastric-glucagon release which averaged 4500-5000 pg/100 g/min in the post infusion period; in contrast, no rise at all in gastric-glucagon release in response to carbatmylcholine was observed during somatostaitin infusion.
G AST R I N R EL EASE
Basal gastrin release was 1I17+33 pg/100 g/min; in the somatostatin experiments, it was abolished to 0+ 10 pg/100 g/min (P<0001). Carhaniylcholine induced a massive gastrin release whichl averaged 5000-10000 pg/100 g/min; this response was totally abolished by somatostatin (Fig. 3 
Discussion
The electrical stimulation of the vagus nerves increases the release of both gatstrin and somiatostatin by the isolated perfused dog stomach; 1 in contrast, such stimulation does not affect gaistricglucagon release. ' We have previously suggested that an absence of innervattion of the canine gastric A cell probably best explaiins this situiation.'I. However, the close interrelationships be- interplaiy, allows us to formulate an alternative mechanism in which somatostaitin releaised by the vagail stimulation would inhibit gaistric-glucaigon release.:' In faict, som.atosta tin hals already been demonstraited to be a potent inhibitor of the gastric A cell under various conditions in vitroà ind in iv'io." 1"' In the present series of experiments, we have shown that exogenous sornatostaitin at a plasma concentraition of 61 nmol/1 (100 ng/ml) completely abolished ba.satl glucagon releaise as well as the gaistric-glucaigon response to catrba.mylcholine. This observaition supports the suggestion thalt endogenous somatostatin, released by vatgal stimulaition, might be involved in the lack of gastric-glucagon response observed in this condition.
The situation with gastrin is apparently somewhat different. Here (1) both electrical vagal stimulaltion' aind acetyl-(or catrbanmyl-) choline infusion' matrkedly stimulaite gatstrin releaise, (2) exogenous somatostatin infusion suppresses basal and carbaimylcholine-induced gaistrin releaise (present results), and (3) somatostaitin-producing D cells and gastrin producing G cells are closely interrelated, 1-1'1 the former having long cytoplazsmic processes terminating on the latter suggesting ailso a paracrine regulatory function.'-If a paracrine secretion of somatostaitin is to be involved to explain the laick of gastric-glucagon response to an electrical stimulation of the valgus nerves, such a mechanism is apparently insufficient to inhibit the release of gaistrin. A differential sensitivity to endogenous somaitostaitin of the glucagon aind gastrin producing cells or at more complete paracrine control of the gastric A cells, than of the gastric G cells, by the D cells may explain these findings. In any case, high concentraitions of somatostatin, such as those used in the present experiments, completely suppress the releaise of glucagon and of gaistrin in response to high concentrations of the cholinergic neurotransmitter analogue, carba.mylcholine. In conclusion, ait a plasmat concentraition of 100 ng/ml, exogenous somatostatin completely inhibits carbanmylcholineinduced glucagon and gastrin releaise from the isolated perfused dog stomach. This observation is compatible with the view that endogenous somatostatin might be involved to explain the lack of gaistric-glucaigon response to vagal stimulation, but does not rule out the alternative proposal.' that the gastric A cell may simply be a non-innervated cell. 
